T32 Training Program in Pediatric Immuno-Oncology and Immunotherapy

项目摘要/摘要 儿科免疫肿瘤学和免疫疗法T32培训计划旨在培养博士后 具有成为高生产率科学家所必需的跨学科技能和知识的研究员 在这个领域。儿科癌症患者的免疫疗法有可能彻底改变我们治疗癌症的方式 该公司致力于治疗儿科癌症患者，并承诺为目前“无法治愈的儿科癌症”提供治疗。这个 这种免疫疗法的高度特异性应该会减少毒性和长期不良反应。然而， 这种治疗方法的成功将取决于我们是否有能力吸引有前途的年轻研究人员进入 菲尔德。尽管成人癌症和儿童癌症之间存在明显的差异，但目前还没有儿童免疫接种。 NIH资助的肿瘤学T32培训计划，我们建议的培训计划填补了这一空白。有一个 迫切需要以发现为基础的研究，特别是确定儿童癌症的免疫格局，以及 加强将免疫治疗方法转化为早期临床研究的研究。 这只能通过提供系统的、严格的儿科免疫肿瘤学和 免疫疗法，而这一T32培训计划满足了这一需求。我们正在申请三个博士后职位 支持我们机构内的免疫肿瘤学和免疫疗法的跨学科培训。儿科 免疫肿瘤学和免疫疗法是一个非常广泛的话题，培训的目的是暴露 受训人员了解最重要的主题，同时也为儿科免疫职业生涯提供量身定制的准备- 肿瘤学相关研究。培训将是基本科学概念和技术的结合，翻译 研究、动物研究和专业发展，包括科学写作和拨款准备。 学员将每年在T32计划的培训日展示他们的工作，培训日将在 与我们的外部咨询委员会(EAC)的现场访问相结合。它将包括研究 学员向教职员工和选管会的专题演讲，选管会成员的专题讲座，以及 选管会对该计划的评估。圣裘德儿童研究医院为 拟议的T32，采用尖端技术，众多核心设施，包括现场产品 制造实践设施，以及致力于培养年轻科学家的敬业教师。此外， 它是NCI唯一一家专门针对儿科癌症的综合性癌症中心的所在地。重要的是 它致力于通过其战略计划和 多个调查员的倡议。圣犹大提供了丰富的智力环境，提供了正式和非正式的互动 在多个机构的讲座和研讨会系列中的实验室和研究计划之间，提供充足的 为受训者提供额外研究培训和职业发展的机会。总之，我们致力于 培训儿科免疫肿瘤学和免疫疗法领域的下一代科学家， 拥有治愈儿童癌症的承诺，与治疗相关的伤害最小。

PROJECT SUMMARY/ABSTRACT The Pediatric Immuno-oncology and Immunotherapy T32 training program is designed to train postdoctoral fellows with the interdisciplinary skills and knowledge that are necessary to become highly productive scientists in this field. Immunotherapy for pediatric cancer patients has the potential to revolutionize how we take care of pediatric cancer patients and holds the promise to provide cures for currently ‘incurable pediatric cancers’. The high specificity of such immunotherapies should reduce toxicity and long-term adverse effects. However, the success of this therapeutic approach will depend on our ability to attract promising young investigators into the field. Despite obvious differences between adult and pediatric cancer, there is currently no pediatric immuno- oncology T32 training program funded by the NIH, and our proposed training program fills this gap. There is an urgent need for discovery-based research, in particular to define the immune landscape of pediatric cancer, and to strengthen research focused on translating immunotherapeutic approaches into early phase clinical studies. This can only be accomplished by providing systematic, rigorous training in pediatric immuno-oncology and immunotherapy, and this T32 training program meets this need. We are requesting three postdoctoral positions to support interdisciplinary training in immuno-oncology and immunotherapy within our institution. Pediatric immuno-oncology and immunotherapy is a very broad topic, and the training has been designed to expose trainees to the most important topics, while also providing tailored preparation for a career in pediatric immuno- oncology-related research. Training will be a combination of basic science concepts and techniques, translational research, animal studies, and professional development, including scientific writing and grant preparation. Trainees will present their work annually as part of the T32 program’s Training Day, which will be held in conjunction with an on-site visit from our External Advisory Committee (EAC). It will comprise research presentations by trainees to program faculty and the EAC, a featured lecture from an EAC member, and evaluation of the program by the EAC. St. Jude Children’s Research Hospital provides an ideal environment for the proposed T32, with cutting edge technologies, numerous core facilities including an onsite Good Manufacturing Practice facility, and dedicated faculty who are committed to training young scientists. Moreover, it is the home of the only NCI comprehensive cancer center that is solely focused on pediatric cancer. Importantly, it is committed to developing the next generation of pediatric immunotherapies through its strategic plan and multi-investigator initiatives. St. Jude provides a rich intellectual environment with formal and informal interaction between laboratories and research programs in multiple institutional lecture and seminar series, providing ample opportunities to trainees for additional research training and career development. In summary, we are committed to training the next generation of scientists in the field of pediatric immuno-oncology and immunotherapy, which holds the promise to cure pediatric cancers with minimal treatment-related harm.